Clinical phenotype, treatment strategy and pregnancy outcome of non‐criteria obstetric antiphospholipid syndrome
Problem To illustrate the clinical features, treatment strategy, and pregnancy outcome of patients with obstetric antiphospholipid syndrome (OAPS), non‐criteria obstetric antiphospholipid syndrome (NC‐OAPS) Method of study A single‐center nested case‐control study was designed. Patients with a diagn...
Gespeichert in:
Veröffentlicht in: | American journal of reproductive immunology (1989) 2023-06, Vol.89 (6), p.e13684-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 6 |
container_start_page | e13684 |
container_title | American journal of reproductive immunology (1989) |
container_volume | 89 |
creator | Li, Jiapo Hou, Yue Zhang, Liyang Li, Fan Liu, Qian Li, Yuanyuan Shen, Hongfei Xiong, Ziyue Huang, Ling Qiao, Chong |
description | Problem
To illustrate the clinical features, treatment strategy, and pregnancy outcome of patients with obstetric antiphospholipid syndrome (OAPS), non‐criteria obstetric antiphospholipid syndrome (NC‐OAPS)
Method of study
A single‐center nested case‐control study was designed. Patients with a diagnosis of OAPS and NC‐OAPS were enrolled. The medical history, coagulation status, and antibody profile data were collected. Patients were given standard anticoagulation therapy with or without glucocorticoids (GC) and/or hydroxychloroquine (HCQ) during pregnancy and were observed for their pregnancy outcome.
Results
A total of 47 patients with OAPS and 120 patients with NC‐OAPS were finally included, of whom 55 patients met the clinical criteria (subgroup C) and 65 met the laboratory criteria (subgroup L). Pregnancy morbidity showed significant differences: gravida, pregnancy loss in OAPS versus NC‐OAPS. The coagulation function was not significantly different between OAPS and NC‐OAPS groups, while TT and FIB were significantly higher in the subgroup C. Thromboelastography (TEG) results showed a significantly lower ANGEL in the NC‐OAPS group, a higher ANGEL and lower EPL, LY30 in the subgroup L. No differences between groups were observed in treatment strategy. The pregnancy outcomes were not significantly different between NC‐OAPS and OAPS groups.
Conclusions
Clinical and laboratory differences were found between OAPS and NC‐OAPS groups in this study. Patients in different subgroups of NC‐OAPS could be identified with different clinical phenotypes. A relatively hypercoagulable status existed in the OAPS group compared to NC‐OAPS, and also in the subgroup L. |
doi_str_mv | 10.1111/aji.13684 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2774894715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2814274504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-ded59e119599bbe9372334ba5c5d54351cf006cec7a16317ed0df4d318c1f29b3</originalsourceid><addsrcrecordid>eNp1kd1qFjEQhoMotlYPvAEJeKLgtsnmb_ewfPjTUvBEj0M2mW3zsZusSZayZ16C1-iVNPpVDwodGGYYnnkZ5kXoNSWntMaZ2ftTymTHn6BjKglpSNerp7UnXDaKk-4Ivch5T0idM_UcHTGphJRSHKO0m3zw1kx4uYEQy7bAB1wSmDJDKDiXZApcb9gEh5cE18EEu-G4FhtnwHHEIYbfP3_Z5Askb3AccoGSvK0bxS83Mdec_OIdzltwqW69RM9GM2V4dV9P0PdPH7_tvjRXXz9f7M6vGssE440DJ3qgtBd9PwxQD28Z44MRVjjBmaB2JERasMpQyagCR9zIHaOdpWPbD-wEvTvoLin-WCEXPftsYZpMgLhm3SrFu54rKir69gG6j2sK9TrddpS3igvCK_X-QNkUc04w6iX52aRNU6L_GKGrEfqvEZV9c6-4DjO4_-S_z1fg7ADc-gm2x5X0-eXFQfIOVqGVDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2814274504</pqid></control><display><type>article</type><title>Clinical phenotype, treatment strategy and pregnancy outcome of non‐criteria obstetric antiphospholipid syndrome</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Li, Jiapo ; Hou, Yue ; Zhang, Liyang ; Li, Fan ; Liu, Qian ; Li, Yuanyuan ; Shen, Hongfei ; Xiong, Ziyue ; Huang, Ling ; Qiao, Chong</creator><creatorcontrib>Li, Jiapo ; Hou, Yue ; Zhang, Liyang ; Li, Fan ; Liu, Qian ; Li, Yuanyuan ; Shen, Hongfei ; Xiong, Ziyue ; Huang, Ling ; Qiao, Chong</creatorcontrib><description>Problem
To illustrate the clinical features, treatment strategy, and pregnancy outcome of patients with obstetric antiphospholipid syndrome (OAPS), non‐criteria obstetric antiphospholipid syndrome (NC‐OAPS)
Method of study
A single‐center nested case‐control study was designed. Patients with a diagnosis of OAPS and NC‐OAPS were enrolled. The medical history, coagulation status, and antibody profile data were collected. Patients were given standard anticoagulation therapy with or without glucocorticoids (GC) and/or hydroxychloroquine (HCQ) during pregnancy and were observed for their pregnancy outcome.
Results
A total of 47 patients with OAPS and 120 patients with NC‐OAPS were finally included, of whom 55 patients met the clinical criteria (subgroup C) and 65 met the laboratory criteria (subgroup L). Pregnancy morbidity showed significant differences: gravida, pregnancy loss in OAPS versus NC‐OAPS. The coagulation function was not significantly different between OAPS and NC‐OAPS groups, while TT and FIB were significantly higher in the subgroup C. Thromboelastography (TEG) results showed a significantly lower ANGEL in the NC‐OAPS group, a higher ANGEL and lower EPL, LY30 in the subgroup L. No differences between groups were observed in treatment strategy. The pregnancy outcomes were not significantly different between NC‐OAPS and OAPS groups.
Conclusions
Clinical and laboratory differences were found between OAPS and NC‐OAPS groups in this study. Patients in different subgroups of NC‐OAPS could be identified with different clinical phenotypes. A relatively hypercoagulable status existed in the OAPS group compared to NC‐OAPS, and also in the subgroup L.</description><identifier>ISSN: 1046-7408</identifier><identifier>EISSN: 1600-0897</identifier><identifier>DOI: 10.1111/aji.13684</identifier><identifier>PMID: 36756665</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>Antibodies, Antiphospholipid ; Antiphospholipid syndrome ; Antiphospholipid Syndrome - diagnosis ; Antiphospholipid Syndrome - drug therapy ; Autoimmune diseases ; Case-Control Studies ; Coagulation ; coagulation function ; Female ; Glucocorticoids ; Humans ; Hydroxychloroquine ; Laboratories ; Morbidity ; non‐criteria obstetric antiphospholipid syndrome ; obstetric antiphospholipid syndrome ; Obstetrics ; Patients ; Phenotypes ; Pregnancy ; Pregnancy Complications - diagnosis ; Pregnancy Outcome</subject><ispartof>American journal of reproductive immunology (1989), 2023-06, Vol.89 (6), p.e13684-n/a</ispartof><rights>2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-ded59e119599bbe9372334ba5c5d54351cf006cec7a16317ed0df4d318c1f29b3</citedby><cites>FETCH-LOGICAL-c3534-ded59e119599bbe9372334ba5c5d54351cf006cec7a16317ed0df4d318c1f29b3</cites><orcidid>0000-0002-3413-3392 ; 0000-0002-4979-3545 ; 0000-0002-9384-2199</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faji.13684$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faji.13684$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36756665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jiapo</creatorcontrib><creatorcontrib>Hou, Yue</creatorcontrib><creatorcontrib>Zhang, Liyang</creatorcontrib><creatorcontrib>Li, Fan</creatorcontrib><creatorcontrib>Liu, Qian</creatorcontrib><creatorcontrib>Li, Yuanyuan</creatorcontrib><creatorcontrib>Shen, Hongfei</creatorcontrib><creatorcontrib>Xiong, Ziyue</creatorcontrib><creatorcontrib>Huang, Ling</creatorcontrib><creatorcontrib>Qiao, Chong</creatorcontrib><title>Clinical phenotype, treatment strategy and pregnancy outcome of non‐criteria obstetric antiphospholipid syndrome</title><title>American journal of reproductive immunology (1989)</title><addtitle>Am J Reprod Immunol</addtitle><description>Problem
To illustrate the clinical features, treatment strategy, and pregnancy outcome of patients with obstetric antiphospholipid syndrome (OAPS), non‐criteria obstetric antiphospholipid syndrome (NC‐OAPS)
Method of study
A single‐center nested case‐control study was designed. Patients with a diagnosis of OAPS and NC‐OAPS were enrolled. The medical history, coagulation status, and antibody profile data were collected. Patients were given standard anticoagulation therapy with or without glucocorticoids (GC) and/or hydroxychloroquine (HCQ) during pregnancy and were observed for their pregnancy outcome.
Results
A total of 47 patients with OAPS and 120 patients with NC‐OAPS were finally included, of whom 55 patients met the clinical criteria (subgroup C) and 65 met the laboratory criteria (subgroup L). Pregnancy morbidity showed significant differences: gravida, pregnancy loss in OAPS versus NC‐OAPS. The coagulation function was not significantly different between OAPS and NC‐OAPS groups, while TT and FIB were significantly higher in the subgroup C. Thromboelastography (TEG) results showed a significantly lower ANGEL in the NC‐OAPS group, a higher ANGEL and lower EPL, LY30 in the subgroup L. No differences between groups were observed in treatment strategy. The pregnancy outcomes were not significantly different between NC‐OAPS and OAPS groups.
Conclusions
Clinical and laboratory differences were found between OAPS and NC‐OAPS groups in this study. Patients in different subgroups of NC‐OAPS could be identified with different clinical phenotypes. A relatively hypercoagulable status existed in the OAPS group compared to NC‐OAPS, and also in the subgroup L.</description><subject>Antibodies, Antiphospholipid</subject><subject>Antiphospholipid syndrome</subject><subject>Antiphospholipid Syndrome - diagnosis</subject><subject>Antiphospholipid Syndrome - drug therapy</subject><subject>Autoimmune diseases</subject><subject>Case-Control Studies</subject><subject>Coagulation</subject><subject>coagulation function</subject><subject>Female</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Laboratories</subject><subject>Morbidity</subject><subject>non‐criteria obstetric antiphospholipid syndrome</subject><subject>obstetric antiphospholipid syndrome</subject><subject>Obstetrics</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - diagnosis</subject><subject>Pregnancy Outcome</subject><issn>1046-7408</issn><issn>1600-0897</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd1qFjEQhoMotlYPvAEJeKLgtsnmb_ewfPjTUvBEj0M2mW3zsZusSZayZ16C1-iVNPpVDwodGGYYnnkZ5kXoNSWntMaZ2ftTymTHn6BjKglpSNerp7UnXDaKk-4Ivch5T0idM_UcHTGphJRSHKO0m3zw1kx4uYEQy7bAB1wSmDJDKDiXZApcb9gEh5cE18EEu-G4FhtnwHHEIYbfP3_Z5Askb3AccoGSvK0bxS83Mdec_OIdzltwqW69RM9GM2V4dV9P0PdPH7_tvjRXXz9f7M6vGssE440DJ3qgtBd9PwxQD28Z44MRVjjBmaB2JERasMpQyagCR9zIHaOdpWPbD-wEvTvoLin-WCEXPftsYZpMgLhm3SrFu54rKir69gG6j2sK9TrddpS3igvCK_X-QNkUc04w6iX52aRNU6L_GKGrEfqvEZV9c6-4DjO4_-S_z1fg7ADc-gm2x5X0-eXFQfIOVqGVDA</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Li, Jiapo</creator><creator>Hou, Yue</creator><creator>Zhang, Liyang</creator><creator>Li, Fan</creator><creator>Liu, Qian</creator><creator>Li, Yuanyuan</creator><creator>Shen, Hongfei</creator><creator>Xiong, Ziyue</creator><creator>Huang, Ling</creator><creator>Qiao, Chong</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3413-3392</orcidid><orcidid>https://orcid.org/0000-0002-4979-3545</orcidid><orcidid>https://orcid.org/0000-0002-9384-2199</orcidid></search><sort><creationdate>202306</creationdate><title>Clinical phenotype, treatment strategy and pregnancy outcome of non‐criteria obstetric antiphospholipid syndrome</title><author>Li, Jiapo ; Hou, Yue ; Zhang, Liyang ; Li, Fan ; Liu, Qian ; Li, Yuanyuan ; Shen, Hongfei ; Xiong, Ziyue ; Huang, Ling ; Qiao, Chong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-ded59e119599bbe9372334ba5c5d54351cf006cec7a16317ed0df4d318c1f29b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Antiphospholipid</topic><topic>Antiphospholipid syndrome</topic><topic>Antiphospholipid Syndrome - diagnosis</topic><topic>Antiphospholipid Syndrome - drug therapy</topic><topic>Autoimmune diseases</topic><topic>Case-Control Studies</topic><topic>Coagulation</topic><topic>coagulation function</topic><topic>Female</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Laboratories</topic><topic>Morbidity</topic><topic>non‐criteria obstetric antiphospholipid syndrome</topic><topic>obstetric antiphospholipid syndrome</topic><topic>Obstetrics</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - diagnosis</topic><topic>Pregnancy Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jiapo</creatorcontrib><creatorcontrib>Hou, Yue</creatorcontrib><creatorcontrib>Zhang, Liyang</creatorcontrib><creatorcontrib>Li, Fan</creatorcontrib><creatorcontrib>Liu, Qian</creatorcontrib><creatorcontrib>Li, Yuanyuan</creatorcontrib><creatorcontrib>Shen, Hongfei</creatorcontrib><creatorcontrib>Xiong, Ziyue</creatorcontrib><creatorcontrib>Huang, Ling</creatorcontrib><creatorcontrib>Qiao, Chong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of reproductive immunology (1989)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jiapo</au><au>Hou, Yue</au><au>Zhang, Liyang</au><au>Li, Fan</au><au>Liu, Qian</au><au>Li, Yuanyuan</au><au>Shen, Hongfei</au><au>Xiong, Ziyue</au><au>Huang, Ling</au><au>Qiao, Chong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical phenotype, treatment strategy and pregnancy outcome of non‐criteria obstetric antiphospholipid syndrome</atitle><jtitle>American journal of reproductive immunology (1989)</jtitle><addtitle>Am J Reprod Immunol</addtitle><date>2023-06</date><risdate>2023</risdate><volume>89</volume><issue>6</issue><spage>e13684</spage><epage>n/a</epage><pages>e13684-n/a</pages><issn>1046-7408</issn><eissn>1600-0897</eissn><abstract>Problem
To illustrate the clinical features, treatment strategy, and pregnancy outcome of patients with obstetric antiphospholipid syndrome (OAPS), non‐criteria obstetric antiphospholipid syndrome (NC‐OAPS)
Method of study
A single‐center nested case‐control study was designed. Patients with a diagnosis of OAPS and NC‐OAPS were enrolled. The medical history, coagulation status, and antibody profile data were collected. Patients were given standard anticoagulation therapy with or without glucocorticoids (GC) and/or hydroxychloroquine (HCQ) during pregnancy and were observed for their pregnancy outcome.
Results
A total of 47 patients with OAPS and 120 patients with NC‐OAPS were finally included, of whom 55 patients met the clinical criteria (subgroup C) and 65 met the laboratory criteria (subgroup L). Pregnancy morbidity showed significant differences: gravida, pregnancy loss in OAPS versus NC‐OAPS. The coagulation function was not significantly different between OAPS and NC‐OAPS groups, while TT and FIB were significantly higher in the subgroup C. Thromboelastography (TEG) results showed a significantly lower ANGEL in the NC‐OAPS group, a higher ANGEL and lower EPL, LY30 in the subgroup L. No differences between groups were observed in treatment strategy. The pregnancy outcomes were not significantly different between NC‐OAPS and OAPS groups.
Conclusions
Clinical and laboratory differences were found between OAPS and NC‐OAPS groups in this study. Patients in different subgroups of NC‐OAPS could be identified with different clinical phenotypes. A relatively hypercoagulable status existed in the OAPS group compared to NC‐OAPS, and also in the subgroup L.</abstract><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36756665</pmid><doi>10.1111/aji.13684</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3413-3392</orcidid><orcidid>https://orcid.org/0000-0002-4979-3545</orcidid><orcidid>https://orcid.org/0000-0002-9384-2199</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1046-7408 |
ispartof | American journal of reproductive immunology (1989), 2023-06, Vol.89 (6), p.e13684-n/a |
issn | 1046-7408 1600-0897 |
language | eng |
recordid | cdi_proquest_miscellaneous_2774894715 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Antibodies, Antiphospholipid Antiphospholipid syndrome Antiphospholipid Syndrome - diagnosis Antiphospholipid Syndrome - drug therapy Autoimmune diseases Case-Control Studies Coagulation coagulation function Female Glucocorticoids Humans Hydroxychloroquine Laboratories Morbidity non‐criteria obstetric antiphospholipid syndrome obstetric antiphospholipid syndrome Obstetrics Patients Phenotypes Pregnancy Pregnancy Complications - diagnosis Pregnancy Outcome |
title | Clinical phenotype, treatment strategy and pregnancy outcome of non‐criteria obstetric antiphospholipid syndrome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A53%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20phenotype,%20treatment%20strategy%20and%20pregnancy%20outcome%20of%20non%E2%80%90criteria%20obstetric%20antiphospholipid%20syndrome&rft.jtitle=American%20journal%20of%20reproductive%20immunology%20(1989)&rft.au=Li,%20Jiapo&rft.date=2023-06&rft.volume=89&rft.issue=6&rft.spage=e13684&rft.epage=n/a&rft.pages=e13684-n/a&rft.issn=1046-7408&rft.eissn=1600-0897&rft_id=info:doi/10.1111/aji.13684&rft_dat=%3Cproquest_cross%3E2814274504%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2814274504&rft_id=info:pmid/36756665&rfr_iscdi=true |